The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic ...

The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high ...

Shares in MaaT Pharma (Euronext: MAAT), a French microbiome company in oncology, closed 25% higher Tuesday. The company ...

German drugmaker STADA Arzneimittel has reported record earnings on revenues growth in its financial first quarter.

Taiwanese biotech PharmaEssentia (TWSE: 6446) is preparing to seek an expanded US label for its long-acting interferon ...

Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley ...

Shanghai-based Mabwell Bioscience (SH: 688062) has secured approval from the Chinese regulator for its first locally ...

Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC).

Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...

Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...